Apple Tree Partners

Tokai Pharmaceuticals raises $23 million in funding

Tuesday, September 20, 2011

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $23 million in a Series D3 financing. The proceeds will be used to support the ongoing clinical development of galeterone (TOK-001), the company’s lead drug candidate, which has completed an initial proof-of-concept phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The financing round included both current investors, Novartis Venture Fund and Apple Tree Partners.

[Read More]